By Kosaku Narioka Takeda Pharmaceutical shares fell sharply after it reported a second-quarter net loss due to impairments on certain products and cut its
Intel provided a better-than-expected revenue forecast for its December quarter, pushing its stock higher in late trading. But the more important news may be